• 1

    Faria MLE, Lu Y, Heaney K, et al. Recombinant human BMP-2 in absorbable collagen sponge enhances bone healing of tibial osteotomies in dogs. Vet Surg 2007;36:122131.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2

    Edwards RB, Seeherman HJ, Bogdanske JJ, et al. Percutaneous injection of recombinant human bone morphogenetic protein-2 in a calcium phosphate paste accelerates healing of a canine tibial osteotomy. J Bone Joint Surg 2004;86-A:14251438.

    • Search Google Scholar
    • Export Citation
  • 3

    Schmoekel HG, Schense JC, Weber FE, et al. Bone healing in the rat and dog with nonglycosylated BMP-2 demonstrating low solubility in fibrin matrices. J Orthop Res 2004;22:376381.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4

    Schmoekel HG, Weber FE, Seiler G, et al. Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix. Vet Surg 2004;33:112118.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5

    Schmoekel HG, Weber FE, Hurter K, et al. Enhancement of bone healing using non-glycosylated rhBMP-2 released from a fibrin matrix in dogs and cats. J Small Anim Pract 2005;46:1721.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Burkus JK, Heim SE, Gornet MF. The effectiveness of rhBMP-2 in replacing autograft: an integrated analysis of three human spine studies. Orthopedics 2004;27:723728.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    Bostrom MP, Camacho NP. Potential role of bone morphogenetic proteins in fracture healing. Clin Orthop Relat Res 1998;(suppl 355):S274S282.

    • Search Google Scholar
    • Export Citation
  • 8

    Sciadini MF, Johnson KD. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res 2000;18:289302.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9

    Li RH, Bouxsein ML, Blake CA, et al. rhBMP-2 injected in a calcium phosphate paste (A-BSM) accelerates healing in the rabbit ulnar osteotomy model. J Orthop Res 2003;21:9971004.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10

    Cheng H, Jiang W, Phillips FM, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg 2003;85A:15441552.

    • Search Google Scholar
    • Export Citation
  • 11

    Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84:21232134.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12

    Welsh EM, Gettinby G, Nolan AM. Comparison of a visual analogue scale and a numerical rating scale for assessment of lameness, using sheep as a model. Am J Vet Res 1993;54:976983.

    • Search Google Scholar
    • Export Citation
  • 13

    Markel MD, Wikenheiser MA, Chao EYS. A study of fracture callus material properties: relationship to torsional strength of bone. J Orthop Res 1990;8:843850.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14

    Warme WJ, Brookes D, Carpenter L, et al. External fixator pin tract infection model in the caprine (goat) tibia: a randomized, prospective, blinded study. Am J Orthop 2004;33:447451.

    • Search Google Scholar
    • Export Citation
  • 15

    Xiang Z, Markel MD. Bromodeoxyuridine immunohistochemistry of epon-embedded undecalcified bone in a canine fracture healing model. J Histochem Cytochem 1995;43:629635.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16

    Markel MD, Bogdanske JJ. The effect of increasing gap width on localized densitometric changes within tibial ostectomies in a canine model. Calcif Tissue Int 1994;54:155159.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17

    Markel MD, Wikenheiser MA, Chao EY. Formation of bone in tibial defects in a canine model: histomorphometric and biomechanical studies. J Bone Joint Surg Am 1991;73:914923.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18

    Hofmeister EH, Egger CM. Transdermal fentanyl patches in small animals. J Am Anim Hosp Assoc 2004;40:468478.

Advertisement

Comparison of two doses of recombinant human bone morphogenetic protein in absorbable collagen sponges for bone healing in dogs

Chad W. SchmiedtComparative Orthopaedic Research Laboratory, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706-1100

Search for other papers by Chad W. Schmiedt in
Current site
Google Scholar
PubMed
Close
 DVM
,
Yan LuComparative Orthopaedic Research Laboratory, Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706-1100

Search for other papers by Yan Lu in
Current site
Google Scholar
PubMed
Close
 MD
,
Kathleen HeaneyFort Dodge Animal Health, 9 Deer Park Dr, Monmouth Junction, NJ 08852

Search for other papers by Kathleen Heaney in
Current site
Google Scholar
PubMed
Close
 DVM
,
Peter MuirComparative Orthopaedic Research Laboratory, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706-1100

Search for other papers by Peter Muir in
Current site
Google Scholar
PubMed
Close
 BVSc, MvetClinStud, PhD
,
Deborah M. AmodieFort Dodge Animal Health, 9 Deer Park Dr, Monmouth Junction, NJ 08852

Search for other papers by Deborah M. Amodie in
Current site
Google Scholar
PubMed
Close
 BA
, and
Mark D. MarkelComparative Orthopaedic Research Laboratory, Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706-1100

Search for other papers by Mark D. Markel in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To determine the effects of 2 doses of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge (rhBMP-2/ACS) on bone healing in dogs.

Animals—27 adult dogs.

Procedures—Dogs underwent a mid-diaphyseal (1-mm) tibial osteotomy (stabilized with external skeletal fixation) and received an ACS containing 0.28 mg (0.2 mg/mL) or 0.56 mg (0.4 mg/mL) of rhBMP-2 or no treatment (control dogs). All dogs were examined daily; bone healing was assessed via radiography and subjective lameness evaluation every 2 weeks. After euthanasia at 8 weeks, tibiae were evaluated biomechanically and histologically.

Results—Control dogs required antimicrobial treatment for pin-site–related complications more frequently than did rhBMP-2/ACS–treated dogs. At 4 and 6 weeks, weight bearing was greater in dogs treated with rhBMP-2/ACS (0.2 mg/mL) than in control dogs, albeit not significantly. Compared with control treatment, both doses of rhBMP-2/ACS accelerated osteotomy healing at 4, 6, and 8 weeks, and the 0.2 mg/mL dose enhanced healing at 2 weeks; healing at 6 weeks was greater for the lower-dose treatment than for the higher-dose treatment. Histologically, healing at 8 weeks was significantly improved for both rhBMP-2/ACS treatments, compared with control treatment. Among groups, biomechanical variables did not differ, although less osteotomy-site failures occurred in rhBMP-2/ACS–treated groups.

Conclusions and Clinical Relevance—In dogs that underwent tibial osteotomy, rhBMP-2/ACS (0.2 mg/mL) appeared to accelerate bone healing and reduce lameness (compared with control treatment) and apparently augmented bone healing more than rhBMP-2/ACS (0.4 mg/mL). Compared with control dogs, rhBMP-2/ACS–treated dogs required antimicrobial treatments less frequently.

Abstract

Objective—To determine the effects of 2 doses of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge (rhBMP-2/ACS) on bone healing in dogs.

Animals—27 adult dogs.

Procedures—Dogs underwent a mid-diaphyseal (1-mm) tibial osteotomy (stabilized with external skeletal fixation) and received an ACS containing 0.28 mg (0.2 mg/mL) or 0.56 mg (0.4 mg/mL) of rhBMP-2 or no treatment (control dogs). All dogs were examined daily; bone healing was assessed via radiography and subjective lameness evaluation every 2 weeks. After euthanasia at 8 weeks, tibiae were evaluated biomechanically and histologically.

Results—Control dogs required antimicrobial treatment for pin-site–related complications more frequently than did rhBMP-2/ACS–treated dogs. At 4 and 6 weeks, weight bearing was greater in dogs treated with rhBMP-2/ACS (0.2 mg/mL) than in control dogs, albeit not significantly. Compared with control treatment, both doses of rhBMP-2/ACS accelerated osteotomy healing at 4, 6, and 8 weeks, and the 0.2 mg/mL dose enhanced healing at 2 weeks; healing at 6 weeks was greater for the lower-dose treatment than for the higher-dose treatment. Histologically, healing at 8 weeks was significantly improved for both rhBMP-2/ACS treatments, compared with control treatment. Among groups, biomechanical variables did not differ, although less osteotomy-site failures occurred in rhBMP-2/ACS–treated groups.

Conclusions and Clinical Relevance—In dogs that underwent tibial osteotomy, rhBMP-2/ACS (0.2 mg/mL) appeared to accelerate bone healing and reduce lameness (compared with control treatment) and apparently augmented bone healing more than rhBMP-2/ACS (0.4 mg/mL). Compared with control dogs, rhBMP-2/ACS–treated dogs required antimicrobial treatments less frequently.

Contributor Notes

Dr. Schmiedt's present address is Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30606.

Supported by Fort Dodge Animal Health.

Presented at the Veterinary Orthopedic Society Conference, Keystone, Colo, February 2006.

The authors thank Vicki Kalscheur for the preparation and staining of histologic samples.

Address correspondence to Dr. Markel.